{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:12:05Z","timestamp":1788952325455,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surveyophthalmol.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Survey of Ophthalmology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.survophthal.2026.04.007","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:19:16Z","timestamp":1778084356000},"page":"1696-1703","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of adjunctive aqueous suppressants for anti-vascular endothelial growth factor therapy: A systematic review"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5644-861X","authenticated-orcid":false,"given":"Kareem","family":"Sadek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salem Abu","family":"Al-Burak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan K.","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Al-Ani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farhad","family":"Ghaseminejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haaris","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parnian","family":"Arjmand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Hutnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5525-1913","authenticated-orcid":false,"given":"Eduardo V.","family":"Navajas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.survophthal.2026.04.007_bib1","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1016\/j.ophtha.2019.09.024","article-title":"Age-related macular degeneration preferred practice pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.survophthal.2026.04.007_bib2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the European society of retina specialists (EURETINA)","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.survophthal.2026.04.007_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ajo.2016.04.017","article-title":"Pro-permeability factors in diabetic macular edema; the diabetic macular edema treated with ozurdex trial","volume":"168","author":"Campochiaro","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.04.007_bib4","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1001\/jamaophthalmol.2019.4557","article-title":"Economic value of anti\u2013vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States","volume":"138","author":"Mulligan","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"10.1016\/j.survophthal.2026.04.007_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41433-020-0961-6","article-title":"Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group","volume":"34","author":"Amoaku","year":"2020","journal-title":"Eye"},{"issue":"4","key":"10.1016\/j.survophthal.2026.04.007_bib6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.survophthal.2026.04.007_bib7","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1167\/iovs.62.9.41","article-title":"Foveal microvascular integrity association with anti-VEGF treatment response for diabetic macular edema","volume":"62","author":"Huang","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"10.1016\/j.survophthal.2026.04.007_bib8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1167\/iovs.64.5.28","article-title":"Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseases","volume":"64","author":"Sharma","year":"2023","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.survophthal.2026.04.007_bib9","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/eye.2015.48","article-title":"Defining response to anti-VEGF therapies in neovascular AMD","volume":"29","author":"Amoaku","year":"2015","journal-title":"Eye"},{"issue":"1","key":"10.1016\/j.survophthal.2026.04.007_bib10","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00417-008-0917-1","article-title":"Prolongation of activity of single intravitreal bevacizumab by adjuvant topical aqueous depressant (Timolol-Dorzolamide)","volume":"247","author":"Byeon","year":"2009","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.04.007_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2019.04.001","article-title":"Retinal oximetry: metabolic imaging for diseases of the retina and brain","volume":"70","author":"Stef\u00e1nsson","year":"2019","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"10.1016\/j.survophthal.2026.04.007_bib12","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/ICB.0000000000000752","article-title":"Topical dorzolamide-timolol with intravitreous anti-vascular endothelial growth factor for retinal vein occlusion: a pilot study","volume":"15","author":"Obeid","year":"2021","journal-title":"Retin Cases Brief Rep"},{"issue":"4","key":"10.1016\/j.survophthal.2026.04.007_bib13","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1001\/jamaophthalmol.2016.0045","article-title":"Topical dorzolamide-timolol with intravitreous anti\u2013vascular endothelial growth factor for neovascular age-related macular degeneration","volume":"134","author":"Sridhar","year":"2016","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.04.007_bib14","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/6794391","article-title":"Combination of intravitreal bevacizumab and topical dorzolamide versus intravitreal bevacizumab alone for diabetic macular edema: a randomized contralateral clinical trial","volume":"2020","author":"Fazel","year":"2020","journal-title":"BioMed Res Int"},{"issue":"5","key":"10.1016\/j.survophthal.2026.04.007_bib15","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1001\/jamaophthalmol.2020.0724","article-title":"Effect of adjuvant topical dorzolamide-timolol vs placebo in neovascular age-related macular degeneration","volume":"138","author":"Hsu","year":"2020","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.survophthal.2026.04.007_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.joco.2019.01.008","article-title":"Efficacy of adjuvant topical timolol\u2013dorzolamide with intravitreal bevacizumab injection in diabetic macular edema: a contralateral eye study","volume":"31","author":"Mirshahi","year":"2019","journal-title":"J Curr Ophthalmol"},{"key":"10.1016\/j.survophthal.2026.04.007_bib17","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.survophthal.2026.04.007_bib18","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7653","key":"10.1016\/j.survophthal.2026.04.007_bib19","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Sch\u00fcnemann","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.survophthal.2026.04.007_bib20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10792-024-03005-z","article-title":"The effect of combination therapy with intravitreal bevacizumab and topical timolol\u2013dorzolamide eye drops on diabetic macular edema: a double-blind randomized controlled trial","volume":"44","author":"Fekri","year":"2024","journal-title":"Int Ophthalmol"},{"issue":"4","key":"10.1016\/j.survophthal.2026.04.007_bib21","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jfo.2022.09.025","article-title":"Acetazolamide and bevacizumab combination therapy versus bevacizumab monotherapy in macular edema secondary to retinal vein occlusion","volume":"46","author":"Karimi","year":"2023","journal-title":"J Fr Ophtalmol"},{"issue":"10","key":"10.1016\/j.survophthal.2026.04.007_bib22","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1097\/IAE.0000000000002293","article-title":"Efficacy of adjuvant topical dorzolamide\u2013timolol in patients with neovascular age-related macular degeneration refractory to anti\u2013vascular endothelial growth factor therapy","volume":"39","author":"Lee","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2026.04.007_bib23","unstructured":"Minkowski J., MacCumber M. Examination of the effect of topical aqueous suppressants on the ef\ufb01cacy of anti-VEGF infections for age-related macular degeneration."},{"issue":"4","key":"10.1016\/j.survophthal.2026.04.007_bib24","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1097\/IAE.0000000000002124","article-title":"Effect of intraocular pressure\u2013lowering medications on neovascular age-related macular degeneration treatment outcomes in the comparison of age-related macular degeneration treatment trials","volume":"39","author":"Rahimy","year":"2019","journal-title":"Retina"},{"key":"10.1016\/j.survophthal.2026.04.007_bib25","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.54829","article-title":"Topical dorzolamide as adjunctive treatment with intravitreal bevacizumab in bilateral diabetic macular edema","author":"Sadr","year":"2024","journal-title":"Cureus [Internet]"},{"issue":"7","key":"10.1016\/j.survophthal.2026.04.007_bib26","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1021\/acs.molpharmaceut.8b00280","article-title":"Theoretical insights into the retinal dynamics of vascular endothelial growth factor in patients treated with ranibizumab, based on an ocular pharmacokinetic\/pharmacodynamic model","volume":"15","author":"Hutton-Smith","year":"2018","journal-title":"Mol Pharm"},{"issue":"10","key":"10.1016\/j.survophthal.2026.04.007_bib27","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/17425255.2024.2401600","article-title":"Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability","volume":"20","author":"Stewart","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"7","key":"10.1016\/j.survophthal.2026.04.007_bib28","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2174\/138161208783877866","article-title":"The development of topically acting carbonic anhydrase inhibitors as antiglaucoma agents","volume":"14","author":"Mincione","year":"2008","journal-title":"Curr Pharm Des"},{"issue":"1","key":"10.1016\/j.survophthal.2026.04.007_bib29","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s004170050013","article-title":"Inhibition of membrane-bound carbonic anhydrase enhances subretinal fluid absorption and retinal adhesiveness","volume":"238","author":"Wolfensberger","year":"2000","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"issue":"163","key":"10.1016\/j.survophthal.2026.04.007_bib30","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2019.0735","article-title":"Fluid and solute transport across the retinal pigment epithelium: a theoretical model","volume":"17","author":"Dvoriashyna","year":"2020","journal-title":"J R Soc Interface"}],"container-title":["Survey of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726000573?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039625726000573?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:23:46Z","timestamp":1788949426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039625726000573"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0039625726000573"],"URL":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.04.007","relation":{},"ISSN":["0039-6257"],"issn-type":[{"value":"0039-6257","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of adjunctive aqueous suppressants for anti-vascular endothelial growth factor therapy: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Survey of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.survophthal.2026.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}